Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004;Épidémiologie des fongémies dans les hôpitaux français non universitaires en 2004 : enquête multicentrique ColBVH

Pathologie Biologie

Volumn 54, Issue 8-9 SPEC.ISS., 2006, Pages 523-530

  Eloy O ^a   Blanc, V ^b   Pina, P ^c   Gaudart, A ^b   Bressolle, M L ^a   Plainvert, C ^a   Decousser, J W ^d   Pangon, B ^a   Allouch, P Y ^a  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b Centre Hospitalier d'Antibes   (France)

^c Centre Hospitalier de Plaisir   (France)

^d Centre hospitalier de Dourdan   (France)

Author keywords

Antifungals; Bloodstream infection; Candida; Candidaemia; France

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PYRROLE DERIVATIVE; ANTIFUNGAL AGENT;

ARTICLE; CANDIDA GLABRATA; CANDIDEMIA; FRANCE; FUNGAL STRAIN; FUNGUS ISOLATION; HEALTH SURVEY; HOSPITAL; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEPTICEMIA; SPECIES; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECT; HOSPITAL PATIENT; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; PROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; FRANCE; HEALTH SURVEYS; HUMANS; INCIDENCE; INPATIENTS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES;

EID: 33750808208     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.07.026     Document Type: Article

References (29)

1. Beck-Sague C., and Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167 5 (1993) 1247-1251
2. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 27 5 (1999) 887-892
3. Jarvis W.R., and Martone W.J. Predominant pathogens in hospital infections. J Antimicrob Chemother 29 Suppl A (1992) 19-24
4. Vincent J.L., Anaissie E., Bruining H., Demajo W., el-Ebiary M., Haber J., et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 24 3 (1998) 206-216
5. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Saiman L., Patterson J., Rinaldi M., et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. 29 2 (1999) 253-258
6. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39 9 (2001) 3254-3259
7. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23 4 (2004) 317-322
8. Wisplinghoff H., Seifert H., Tallent S.M., Bischoff T., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22 8 (2003) 686-691
9. Marchetti O., Bille J., Fluckiger U., Eggimann P., Ruef C., Garbino J., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 38 3 (2004) 311-320
10. Anatoliotaki M., Valatas V., Mantadakis E., Apostolakou H., Mavroudis D., Georgoulias V., et al. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection 32 2 (2004) 65-71
11. Ortega M., Rovira M., Almela M., Marco F., de la Bellacasa J.P., Martinez J.A., et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann. Hematol. 84 1 (2005) 40-46
12. Cuenca-Estrella M., Moore C.B., Barchiesi F., Bille J., Chryssanthou E., Denning D.W., et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 9 6 (2003) 467-474
13. Krcmery Jr. V., Oravcova E., Spanik S., Mrazova-Studena M., Trupl J., Kunova A., et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J. Antimicrob. Chemother. 41 3 (1998) 373-380
14. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., and Wenzel R.P. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn. Microbiol. Infect. Dis. 30 2 (1998) 121-129
15. Pfaller M.A., and Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10 Suppl 1 (2004) 11-23
16. Pfaller M.A., and Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40 10 (2002) 3551-3557
17. Barry A.L., Pfaller M.A., Rennie R.P., Fuchs P.C., and Brown S.D. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob. Agents Chemother. 46 6 (2002) 1781-1784
18. Matar M.J., Ostrosky-Zeichner L., Paetznick V.L., Rodriguez J.R., Chen E., and Rex J.H. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47 5 (2003) 1647-1651
19. Wanger A., Mills K., Nelson P.W., and Rex J.H. Comparison of E-test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39 11 (1995) 2520-2522
20. Law D., Moore C.B., and Denning D.W. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J. Antimicrob. Chemother. 40 1 (1997) 109-112
21. Sobel J.D. Management of infections caused by Candida glabrata. Curr. Infect. Dis. Rep. 2 5 (2000) 424-428
22. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., and Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol. 43 5 (2005) 2155-2162
23. Mary C., Goudard M., Blancard A., Quilici M., and Regli P. Synergic effect of 5-fluorocytosine and imidazole derivatives against yeast strains resistant to 5-fluorocytosine. Ann. Biol. Clin. (Paris) 47 9 (1989) 546-549
24. Sanglard D., Ischer F., Calabrese D., Majcherczyk P.A., and Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43 11 (1999) 2753-2765
25. Rex J.H., Walsh T.J., Sobel J.D., Filler S.G., Pappas P.G., Dismukes W.E., et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30 4 (2000) 662-678
26. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J. Clin. Microbiol. 43 8 (2005) 3807-3810
27. Sfar, SPIFL, SRLF. Conférence de consensus commune. Prise en charge des candidoses et aspergilloses invasives de l'adulte (2004)
28. Rubio Calvo M.C., Gil J., Ramirez de Ocariz I., Benito R., and Rezusta A. In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp. Rev. Esp. Quimioter. 16 2 (2003) 227-232
29. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47 10 (2003) 3149-3154